GCM
ABBV icon

Gladius Capital Management’s AbbVie ABBV Stock Holding History

Gladius Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$854K Sell
3,925
-3,647
-48% -$809K 0.04% 96
2025
Q4 		$1.73M Buy
+7,572
New +$1.72M 0.09% 80
2025
Q3 		– Sell
-1,173
Closed -$239K – 103
2025
Q2 		$218K Sell
1,173
-4,294
-79% -$798K 0.08% 61
2025
Q1 		$1.15M Sell
5,467
-3,590
-40% -$698K 0.3% 56
2024
Q4 		$1.61M Buy
9,057
+2,667
+42% +$490K 0.17% 62
2024
Q3 		$1.26M Buy
6,390
+2,149
+51% +$401K 0.15% 65
2024
Q2 		$727K Buy
4,241
+1,798
+74% +$298K 0.09% 92
2024
Q1 		$445K Buy
+2,443
New +$421K 0.15% 103
2023
Q4 		– Sell
-8,844
Closed -$1.29M – 313
2023
Q3 		$1.32M Buy
8,844
+3,455
+64% +$507K 0.06% 115
2023
Q2 		$726K Buy
5,389
+3,632
+207% +$533K 0.04% 110
2023
Q1 		$280K Sell
1,757
-953
-35% -$146K 0.02% 142
2022
Q4 		$438K Sell
2,710
-6,357
-70% -$975K 0.03% 107
2022
Q3 		$1.22M Buy
9,067
+7,374
+436% +$1.06M 0.05% 102
2022
Q2 		$260K Sell
1,693
-5,325
-76% -$814K 0.01% 152
2022
Q1 		$1.14M Buy
7,018
+5,280
+304% +$767K 0.08% 61
2021
Q4 		$236K Buy
1,738
+1,001
+136% +$118K 0.02% 170
2021
Q3 		$80K Buy
737
+302
+69% +$34.5K 0.01% 109
2021
Q2 		$49K Buy
+435
New +$49K ﹤0.01% 117
2020
Q4 		– Sell
-3,104
Closed -$298K – 164
2020
Q3 		$272K Buy
+3,104
New +$292K 0.03% 156
2020
Q1 		– Sell
-426
Closed -$38K – 126
2019
Q4 		$38K Sell
426
-5,485
-93% -$455K ﹤0.01% 158
2019
Q3 		$448K Sell
5,911
-349
-6% -$23.9K 0.02% 181
2019
Q2 		$460K Sell
6,260
-19,882
-76% -$1.56M 0.03% 135
2019
Q1 		$2.11M Sell
26,142
-1,294
-5% -$106K 0.12% 86
2018
Q4 		$2.53M Buy
27,436
+24,291
+772% +$2.14M 0.12% 81
2018
Q3 		$297K Sell
3,145
-4,567
-59% -$433K 0.03% 64
2018
Q2 		$715 Buy
+7,712
New +$753K 0.07% 60

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gladius Capital Management's ABBV Position: Q1 2026 in Review

Gladius Capital Management reduced its AbbVie (ABBV) stake by 48% in Q1 2026, selling an estimated $809K and leaving 3,925 shares worth $854K. The position accounts for 0.04% of the portfolio, ranked #96.

Gladius Capital Management first reported a position in ABBV in Q2 2018 and has held it in 26 quarters since. The position peaked at $2.53M in Q4 2018. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Gladius Capital Management held 3,925 shares of AbbVie worth $854K as of Q1 2026.
  • Gladius Capital Management sold 3,647 AbbVie shares in Q1 2026, an estimated $809K.
  • AbbVie made up 0.04% of Gladius Capital Management's portfolio in Q1 2026, its #96 holding.
  • Gladius Capital Management first reported a position in AbbVie in Q2 2018 and has held it in 26 quarters since.
  • Gladius Capital Management's AbbVie position peaked at $2.53M in Q4 2018.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Gladius Capital Management's 13F filing for Q1 2026, filed 7 May 2026.